DOCSLIB.ORG

Tuesday Scienti Ic Session Listings 452–638 Information at a Glance

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Tuesday Scienti� Ic Session Listings 452–638 Information at a Glance Chicago | October 17-21 Tuesday Scienti ic Session Listings 452–638 Information at a Glance Important Phone Numbers Annual Meeting Headquarters Office Mercy Hospital Key to Poster Floor by Themes Logistics and Programming 2525 S Michigan Avenue The poster floor begins with Theme A and ends Logistics Chicago, IL 60616 with Theme H. Refer to the poster floor map at McCormick Place: Hall A, (312) 791‑6700 (312) 567‑2000 the end of this booklet. Programming Physicians Immediate Care Theme McCormick Place: Hall A, (312) 791‑6705 811 S. State Street A Development Chicago, IL 60605 B Neural Excitability, Synapses, and Glia: Volunteer Leadership Lounge (312) 566‑9510 Cellular Mechanisms McCormick Place: S505A, (312) 791‑6735 Walgreens Pharmacy C Disorders of the Nervous System General Information Booths (closest to McCormick Place) D Sensory and Motor Systems McCormick Place: 3405 S. Martin Luther King Drive E Integrative Systems: Neuroendocrinology, Gate 3 Lobby, (312) 791‑6724 Chicago, IL 60616 Neuroimmunology and Homeostatic Challenge Hall A (312) 791‑6725 (312) 326‑4064 F Cognition and Behavior Press Offices Venues G Novel Methods and Technology Development Press Room McCormick Place H History, Teaching, Public Awareness, and McCormick Place: Room S501ABC 2301 S. Martin Luther King Drive Societal Impacts in Neuroscience (312) 791‑6730 Chicago, IL 60616 Exhibit Management Fairmont Chicago, Millennium Park Hotel Note: Theme H Posters will be located in Hall A McCormick Place: Hall A, (312) 791‑6740 200 N. Columbus Drive beginning at 1 p.m. on Saturday, Oct. 17, and will Chicago, IL 60601 remain posted until 5 p.m., Sunday, Oct. 18. First Aid and Hospital Numbers (312) 565‑8000 First Aid Station McCormick Place: Level 2.5S, (312) 791‑6060 Hyatt Regency Chicago Downtown Hotel (not connected to McCormick Place) 151 E. Wacker Drive Chicago, IL 60601 (312) 565‑1234 Cover Image: Confocal image of a cholinergic single‑cell microculture. This neuron has been partially depleted of clathrin by RNAi. It is expressing GFP (pseudocolored orange‑yellow) and has been stained to show synapses (red) and clathrin (blue). Autaptic electrophysiological recordings in these cultures, together with electron microscopy, live cell imaging, or immunofluorescence, reveal that clathrin levels set limits for presynaptic plasticity. Francisco J. López‑Murcia, Stephen J. Royle, and Artur Llobet, 2014, The Journal of Neuroscience, 34(25): 8618‑8629. Complete Session Listing Tuesday AM SPECIAL LECTURE McCormick Place SYMPOSIUM McCormick Place 452. • Strange Synapses and Circuits of the Basal 454. All-Optical Interrogation of Neural Circuits — CME Ganglia — CME Tue. 8:30 AM - 11:00 AM — S100B Tue. 8:30 AM - 9:40 AM — Hall B1 Chair: M. HAUSSER Speaker: B. SABATINI, Harvard Med. Sch. Co-Chair: V. EMILIANI The basal ganglia are a phylogenetically old and This symposium will describe the nexus of dramatic evolutionarily conserved set of nuclei crucial for goal- recent developments in optogenetic probes, genetically oriented motor action. Nevertheless, many aspects of their encoded activity sensors, and novel microscopies, which circuitry, function, and regulation remain mysterious. Sabatini together allow the activity of neural circuits to be recorded will present recent work from his group revealing complex and manipulated using entirely light. Such an “all-optical” and unexpected interactions between nuclei of the basal approach promises to illuminate many fundamental ganglia. These include the surprisingly widespread use of challenges in neuroscience, including transforming our multiple fast acting neurotransmitters by neuromodulatory search for the neural code and the links between neural systems. The results will be discussed in terms of action circuit activity and behavior. initiation and reinforcement. 8:30 454.01 Introduction. 8:35 454.02 All-optical electrophysiology. A. COHEN. Harvard SYMPOSIUM McCormick Place Univ. 9:10 454.03 Spatially selective holographic photoactivation and 453. Synapse Formation and Neurodevelopmental functional fluorescence imaging in freely behaving mice. .V — CME Disorders EMILIANI. Univ. of Paris. Tue. 8:30 AM - 11:00 AM — S100A 9:45 454.04 All-optical neurophysiology in the awake mouse. K. AM Tues. Chair: L. MEI DEISSEROTH. Stanford Univ. Co-Chair: C. LEGAY 10:20 454.05 Targeting functional cortical ensembles using all- Neural transmission and plasticity are critical to how we optical interrogation during behaviour. M. HAUSSER. Univ. perceive, think, and react to the world. This relies on Col. London. synapses. Inappropriate formation of synapses has been implicated in neuropsychiatric disorders and loss of synaptic 10:55 454.06 Closing Remarks. connection may lead to neurodegenerative disorders. This symposium will provide insights into mechanisms that govern synapse formation and stability in various model MINISYMPOSIUM McCormick Place systems and shed light on pathophysiological mechanisms. 455. Modern Approaches Toward More Predictive Mouse 8:30 453.01 Introduction. Models of Neurodegenerative Diseases — CME 8:35 Molecular mechanisms controlling synapse 453.02 Tue. 8:30 AM - 11:00 AM — S406A formation and stability. J. PIELAGE. Friedrich Miescher Inst. for Biomed. Res. Chair: G. R. HOWELL Co-Chair: B. T. LAMB 9:10 453.03 MuSK and Wnts, their roles in synapse formation Animal models of neurodegenerative diseases have and maintenance. C. LEGAY. Paris Descartes Univ. provided important insights into the pathophysiology of 9:45 453.04 Genetic disorders of neuromuscular transmission. disease and suggested potential avenues for therapies. H. LOCHMÜLLER. Newcastle Univ. However, translation of these findings to the clinic has been limited. The latest advances in modeling different 10:20 453.05 Powering the brain: Glycolytic enzymes localize to neurodegenerative disease processes will be presented, as synapses under energy stress to support synaptic function. well as the cutting-edge technologies/methodologies that are D. A. COLÓN-RAMOS. Yale Univ. revolutionizing the field and should provide more predictive 10:55 453.06 Closing Remarks. models for neurodegenerative diseases. 8:30 455.01 Introduction. 8:35 455.02 • Modeling disease for therapy development in amyotrophic lateral sclerosis and frontotemporal dementia with C9orf72 expansion. C. LAGIER-TOURENNE. UC San Diego. 8:55 455.03 Conditional and controllable models of Alzheimer’s disease for improved spatial and temporal control of transgene expression. J. JANKOWSKY. Baylor Col. of Med. 9:15 455.04 Novel animal models to study innate immunity and neurodegeneration. B. T. LAMB. Cleveland Clin. Fndtn. • Indicated a real or perceived conflict of interest, see page 160 for details. Neuroscience 2015 | Tuesday AM | 1 Indicates a high school or undergraduate student presenter. * Indicates abstract’s submitting author 9:35 455.05 Systems genetics of complex neurodegenerative MINISYMPOSIUM McCormick Place diseases. G. CARTER. The Jackson Lab. 457. Mood and Reward Networks in Chronic Pain 9:55 455.06 Applications of CRISPR-Cas9 for genome editing Conditions — CME in the mammalian brain. M. HEIDENREICH. Broad Inst. of MIT and Harvard. Tue. 8:30 AM - 11:00 AM — S103 10:15 455.07 Integrated mouse genetic and genomic approach Chair: V. ZACHARIOU to dissect Huntington’s disease pathogenesis. N. WANG. Co-Chair: I. YALCIN UCLA. This session presents new perspectives on mechanisms modulating sensory and affective components of chronic 10:35 455.08 Closing Remarks. pain. The panel will emphasize studies on networks involved in mood, reward, and motivation. Speakers will cover areas of investigation related to adaptations in cortical and striatal MINISYMPOSIUM McCormick Place networks under chronic pain conditions, the impact of pain in cortical plasticity and stress/anxiety disorders, the 456. Brainy and Handy: What Robotics and Prosthetics Can mechanisms by which the brain reward center modulates Learn from Touch Receptors in the Hand — CME motivation under chronic pain states, and the intracellular Tue. 8:30 AM - 11:00 AM — S105 targets of antidepressants in the brain reward center. Chair: E. P. GARDNER 8:30 457.01 Introduction. To honor Vernon Mountcastle, experts from somatosensory 8:35 457.02 The impact of pain on motivation. N. SCHWARTZ. neurophysiology, psychophysics, and bioengineering UCSF. will present studies of how the sense of touch might be translated for use in prosthetic or robotic hands. Speakers 8:55 457.03 How expectations, instructions, and beliefs shape will define the components of intelligent manipulative pain and aversive learning. L. ATLAS. NIH. sensors based on biological models in the hand. Touch 9:15 457.04 Presynaptic and postsynaptic mechanisms for receptors detect object shape, edges and texture, and chronic pain and anxiety. M. ZHUO. Univ. of Toronto. monitor grip force. Multisensor networks enhance touch information enabling translational application to adaptive 9:35 457.05 The anterior cingulate cortex as a substrate for mechanical hands. chronic pain-induced depression: Molecular, lesional and optogenetic evidences. I. YALCIN. UPR3212 CNRS. 8:30 456.01 Introduction. 9:55 457.06 Nucleus Accumbens subregions dissociate 8:35 456.02 Coding and use of tactile signals in object encoding of values for reward and pain. V. APKARIAN. manipulation tasks. R. S. JOHANSSON. Univ. Umea. Northwestern Univ. 8:55 456.03 Mechanisms of mechanosensory signaling in 10:15 457.07 Intracellular pathways in the Nucleus Accumbens discriminative touch receptors. E. A. LUMPKIN. Columbia
Load more

Recommended publications
  • Effects of Chronic Systemic Low-Impact Ampakine Treatment On
    Biomedicine & Pharmacotherapy 105 (2018) 540–544 Contents lists available at ScienceDirect Biomedicine & Pharmacotherapy journal homepage: www.elsevier.com/locate/biopha Effects of chronic systemic low-impact ampakine treatment on neurotrophin T expression in rat brain ⁎ Daniel P. Radin , Steven Johnson, Richard Purcell, Arnold S. Lippa RespireRx Pharmaceuticals, Inc., 126 Valley Road, Glen Rock, NJ, 07452, United States ARTICLE INFO ABSTRACT Keywords: Neurotrophin dysregulation has been implicated in a large number of neurodegenerative and neuropsychiatric Ampakine diseases. Unfortunately, neurotrophins cannot cross the blood brain barrier thus, novel means of up regulating BDNF their expression are greatly needed. It has been demonstrated previously that neurotrophins are up regulated in Cognitive enhancement response to increases in brain activity. Therefore, molecules that act as cognitive enhancers may provide a LTP clinical means of up regulating neurotrophin expression. Ampakines are a class of molecules that act as positive Neurotrophin allosteric modulators of AMPA-type glutamate receptors. Currently, they are being developed to prevent opioid- NGF induced respiratory depression without sacrificing the analgesic properties of the opioids. In addition, these molecules increase neuronal activity and have been shown to restore age-related deficits in LTP in aged rats. In the current study, we examined whether two different ampakines could increase levels of BDNF and NGF at doses that are active in behavioral measures of cognition. Results demonstrate that ampakines CX516 and CX691 induce differential increases in neurotrophins across several brain regions. Notable increases in NGF were ob- served in the dentate gyrus and piriform cortex while notable BDNF increases were observed in basolateral and lateral nuclei of the amygdala.
    [Show full text]
  • From Inverse Agonism to 'Paradoxical Pharmacology' Richard A
    International Congress Series 1249 (2003) 27-37 From inverse agonism to 'Paradoxical Pharmacology' Richard A. Bond*, Kenda L.J. Evans, Zsirzsanna Callaerts-Vegh Department of Pharmacological and Pharmaceutical Sciences, University of Houston, 521 Science and Research Bldg 2, 4800 Caltioun, Houston, TX 77204-5037, USA Received 16 April 2003; accepted 16 April 2003 Abstract The constitutive or spontaneous activity of G protein-coupled receptors (GPCRs) and compounds acting as inverse agonists is a recent but well-established phenomenon. Dozens of receptor subtypes for numerous neurotransmitters and hormones have been shown to posses this property. However, do to the apparently low percentage of receptors in the spontaneously active state, the physiologic relevance of these findings remains questionable. The possibility that the reciprocal nature of the effects of agonists and inverse agonists may extend to cellular signaling is discussed, and that this may account for the beneficial effects of certain p-adrenoceptor inverse agonists in the treatment of heart failure. © 2003 Elsevier Science B.V. All rights reserved. Keywords. Inverse agonism; GPCR; Paradoxical pharmacology 1. Brief history of inverse agonism at G protein-coupled receptors For approximately three-quarters of a century, ligands that interacted with G protein- coupled receptors (GPCRs) were classified either as agonists or antagonists. Receptors were thought to exist in a single quiescent state that could only induce cellular signaling upon agonist binding to the receptor to produce an activated state of the receptor. In this model, antagonists had no cellular signaling ability on their own, but did bind to the receptor and prevented agonists from being able to bind and activate the receptor.
    [Show full text]
  • Supplemental Table 1 Enriched Genes in Cortical Astrocytes from Aged
    Supplemental Table 1 Enriched genes in cortical astrocytes from aged and young-adult mice * Genes were present in the astrocyte module from the WGCNA analysis, and contains astrocyte enriched genes compared to microglia and oligodendrocytes # = Fold change of aged astrocyte expression over the average expression of all analyzed samples (microglia, astrocytes: young, old, with and without myelin contamination) $ ; aged = genes only present in the aged astrocyte top 1000 list (used to compare with lists from Cahoy, Lovatt, Doyle; see Fig. 4B), all = genes present in all astrocyte top 1000 lists Gene Symbol* Aged astr. (log2) Young astr.(log2) FC (aged/ aver.)# Location Ptprz1 15.37 15.02 18.76 Plasma Membrane Slc7a10 14.49 14.44 18.28 Plasma Membrane Gjb6 15.13 14.42 18.18 Plasma Membrane Dclk1 14.63 14.28 17.18 unknown Hes5 15.69 15.55 16.94 Nucleus Fgfr3 15.27 14.46 16.54 Plasma Membrane Entpd2 13.85 13.56 15.92 Cytoplasm Grin2c 14.93 14.87 15.75 Plasma Membrane Slc1a2 15.51 15.39 15.58 Plasma Membrane Fjx1 14.36 13.98 14.52 Extracellular Space Slc6a1 14.20 14.16 14.47 Plasma Membrane Kcnk1 12.93 13.49 14.43 Plasma Membrane Ppap2b 16.16 16.10 14.37 Plasma Membrane Fam20a 14.48 14.72 14.00 Extracellular Space Dbx2 13.68 13.32 13.99 Nucleus Itih3 13.93 13.93 13.94 Extracellular Space Htra1 17.12 16.91 13.92 Extracellular Space Atp1a2 14.59 14.48 13.73 Plasma Membrane Scg3 15.71 15.72 13.68 Extracellular Space F3 15.59 15.08 13.51 Plasma Membrane Mmd2 14.22 14.60 13.50 unknown Nrcam 13.73 13.88 13.47 Plasma Membrane Cldn10a 13.37 13.57 13.46
    [Show full text]
  • Spring-Summer 2016
    Spring/Summer 2016 Division of Adult Audiology Department of Otolaryngology Website: hearing.wustl.edu NEW TEXTBOOK! CURRENT RESEARCH RESEARCH CONT. The Hearing Aid Research Lab is If you would like more infor- currently completing a study ex- mation please contact Kristi amining differences in speech Oeding by phone at 314-362- recognition and personal prefer- 7496 or by e-mail at ences between three different set- [email protected] tings in a hearing aid. The prelim- inary data on the research study WEST CO. IS MOVING! was presented at the national meeting of the American Acade- We are excited to announce my of Audiology in Phoenix, that Drs. Diane Duddy and AZ in April. Jennifer Listenberger along with ENT are moving to a The Division of Adult Audiology brand new location with new at Washington University in St. sound booths at the end of May Louis School of Medicine is con- They will be moving from their Drs. Kristi Oeding, Jennifer ducting a research study to deter- current location to Medical Listenberger, and Steve mine the degree of hearing loss Office Building 1, Suite 123, Smith recently had their text- that a person can have to use a 1040 N. Mason Road, Creve book, The Audiogram Work- loudspeaker system without the Coeur, MO 63141. For ap- book published by Thieme need for hearing aids. Partici- Medical Publishers. The text- pants must be 18 years of age or book provides real-world cases older and have either normal for students, audiologists, and hearing or bilateral inner ear physicians to learn and provide hearing loss.
    [Show full text]
  • Misophonia Tech Reviews
    TECH REVIEWS Tech Reviews SECTION EDITORS Misophonia BY CURT WETMORE ecreased sound tolerance is a should be made aware of this prior to being common audiologic complaint. encouraged to do their own research in Unlike the classic characteristics the area. With the growing awareness and Dr David Pothier, MSc, of hyperacusis whereby a curiosity around misophonia, I wanted MBChB, FRCS(ORL-HNS), D Staff Neurologist, patient is sensitive to the frequency or to highlight some online resources that Assistant Professor, volume of a sound, misophonia is a strong patients have access to: University of Toronto, emotional and psychological reaction to a Department of Otolaryngology, Head and Neck Surgery, sound with a specific pattern or meaning. www.misophonia.com Toronto General Hospital, These trigger sounds can range from This website contains information on University Health Network, noises produced by other people (i.e. lip Toronto, Canada. common symptoms and triggers and smacking, chewing sounds, or pen clicking) E: [email protected] introduces visitors to treatment options to environmental noises (i.e. a distant such as cognitive behavioural therapy engine or a cat purring). Misophonic (CBT) and tinnitus retraining therapy (TRT). reactions to a trigger sound can include The website also contains downloadable feelings of extreme rage, anxiety, resources which include educational frustration and disgust. brochures and explanation letter templates. First proposed in 2000, misophonia The highlight of this website is the online remains a complex and elusive support forum: a virtual environment phenomenon. It is currently not included where you can create a profile, connect with Carolyn Falls, MClSc, in the DSM-5 but has attracted media other people suffering with misophonia, Clinical Audiologist, Lecturer, attention and public awareness in recent read personal experiences and engage University of Toronto, Department years.
    [Show full text]
  • Guthrie Cdna Resource Center
    cDNA Resource Center cDNA Resource Center Catalog cDNA Resource Center Missouri University of Science and Technology 400 W 11th Rolla, MO 65409 TEL: (573) 341-7610 FAX: (573) 341-7609 EMAIL: [email protected] www.cdna.org September, 2008 1 cDNA Resource Center Visit our web site for product updates 2 cDNA Resource Center The cDNA Resource Center The cDNA Resource Center is a service provided by the faculty of the Department of Biological Sciences of Missouri University of Science and Technology. The purpose of the cDNA Resource Center is to further scientific investigation by providing cDNA clones of human proteins involved in signal transduction processes. This is achieved by providing high quality clones for important signaling proteins in a timely manner. By high quality, we mean that the clones are • Sequence verified • Propagated in a versatile vector useful in bacterial and mammalian systems • Free of extraneous 3' and 5' untranslated regions • Expression verified (in most cases) by coupled in vitro transcription/translation assays • Available in wild-type, epitope-tagged and common mutant forms (e.g., constitutively- active or dominant negative) By timely, we mean that the clones are • Usually shipped within a day from when you place your order. Clones can be ordered from our web pages, by FAX or by phone. Within the United States, clones are shipped by overnight courier (FedEx); international orders are shipped International Priority (FedEx). The clones are supplied for research purposes only. Details on use of the material are included on the Material Transfer Agreement (page 3). Clones are distributed by agreement in Invitrogen's pcDNA3.1+ vector.
    [Show full text]
  • Neuroenhancement in Healthy Adults, Part I: Pharmaceutical
    l Rese ca arc ni h li & C f B o i o l e Journal of a t h n Fond et al., J Clinic Res Bioeth 2015, 6:2 r i c u s o J DOI: 10.4172/2155-9627.1000213 ISSN: 2155-9627 Clinical Research & Bioethics Review Article Open Access Neuroenhancement in Healthy Adults, Part I: Pharmaceutical Cognitive Enhancement: A Systematic Review Fond G1,2*, Micoulaud-Franchi JA3, Macgregor A2, Richieri R3,4, Miot S5,6, Lopez R2, Abbar M7, Lancon C3 and Repantis D8 1Université Paris Est-Créteil, Psychiatry and Addiction Pole University Hospitals Henri Mondor, Inserm U955, Eq 15 Psychiatric Genetics, DHU Pe-psy, FondaMental Foundation, Scientific Cooperation Foundation Mental Health, National Network of Schizophrenia Expert Centers, F-94000, France 2Inserm 1061, University Psychiatry Service, University of Montpellier 1, CHU Montpellier F-34000, France 3POLE Academic Psychiatry, CHU Sainte-Marguerite, F-13274 Marseille, Cedex 09, France 4 Public Health Laboratory, Faculty of Medicine, EA 3279, F-13385 Marseille, Cedex 05, France 5Inserm U1061, Idiopathic Hypersomnia Narcolepsy National Reference Centre, Unit of sleep disorders, University of Montpellier 1, CHU Montpellier F-34000, Paris, France 6Inserm U952, CNRS UMR 7224, Pierre and Marie Curie University, F-75000, Paris, France 7CHU Carémeau, University of Nîmes, Nîmes, F-31000, France 8Department of Psychiatry, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Eschenallee 3, 14050 Berlin, Germany *Corresponding author: Dr. Guillaume Fond, Pole de Psychiatrie, Hôpital A. Chenevier, 40 rue de Mesly, Créteil F-94010, France, Tel: (33)178682372; Fax: (33)178682381; E-mail: [email protected] Received date: January 06, 2015, Accepted date: February 23, 2015, Published date: February 28, 2015 Copyright: © 2015 Fond G, et al.
    [Show full text]
  • Differential Gene Expression in Oligodendrocyte Progenitor Cells, Oligodendrocytes and Type II Astrocytes
    Tohoku J. Exp. Med., 2011,Differential 223, 161-176 Gene Expression in OPCs, Oligodendrocytes and Type II Astrocytes 161 Differential Gene Expression in Oligodendrocyte Progenitor Cells, Oligodendrocytes and Type II Astrocytes Jian-Guo Hu,1,2,* Yan-Xia Wang,3,* Jian-Sheng Zhou,2 Chang-Jie Chen,4 Feng-Chao Wang,1 Xing-Wu Li1 and He-Zuo Lü1,2 1Department of Clinical Laboratory Science, The First Affiliated Hospital of Bengbu Medical College, Bengbu, P.R. China 2Anhui Key Laboratory of Tissue Transplantation, Bengbu Medical College, Bengbu, P.R. China 3Department of Neurobiology, Shanghai Jiaotong University School of Medicine, Shanghai, P.R. China 4Department of Laboratory Medicine, Bengbu Medical College, Bengbu, P.R. China Oligodendrocyte precursor cells (OPCs) are bipotential progenitor cells that can differentiate into myelin-forming oligodendrocytes or functionally undetermined type II astrocytes. Transplantation of OPCs is an attractive therapy for demyelinating diseases. However, due to their bipotential differentiation potential, the majority of OPCs differentiate into astrocytes at transplanted sites. It is therefore important to understand the molecular mechanisms that regulate the transition from OPCs to oligodendrocytes or astrocytes. In this study, we isolated OPCs from the spinal cords of rat embryos (16 days old) and induced them to differentiate into oligodendrocytes or type II astrocytes in the absence or presence of 10% fetal bovine serum, respectively. RNAs were extracted from each cell population and hybridized to GeneChip with 28,700 rat genes. Using the criterion of fold change > 4 in the expression level, we identified 83 genes that were up-regulated and 89 genes that were down-regulated in oligodendrocytes, and 92 genes that were up-regulated and 86 that were down-regulated in type II astrocytes compared with OPCs.
    [Show full text]
  • Misophonia-Hub.Org
    MISOPHONIA An information sheet for adults with misophonia THIS FACTSHEET ABOUT MISOPHONIA ALLOWS YOU TO RECORD ANY TYPE OF MISO- HOW TO SUPPORT ADULTS WITH MISOPHONIA IN STUDENT SETTINGS, OR OTHER PHONIA YOU MAY EXPERIENCE. PEOPLE WITH MISOPHONIA SOMETIMES STRUGGLE TO ENVIRONMENTS. NUMBERS IN THE TEXT REFER TO SCIENTIFIC REPORTS USED IN FIND THE APPROPRIATE SUPPORT SO THIS FORM IS DESIGNED TO BE PRINTED AND WRITING THIS FACTSHEET (LISTED ON PAGE 2). FUTHER MISOPHONIA RESOURCES FOR SHARED WITH RELEVANT PROFESSIONALS (EG. FAMILY DOCTOR, STUDENT SUPPORT ADULTS, CHILDREN, PARENTS, TEACHERS, CLINICIANS, AND RESEARCHERS CAN BE OFFICE). BELOW WE ALSO PROVIDE A LINK TO OUR ONLINE RESOURCES SHOWING FOUND AT WWW.MISOPHONIA-HUB.ORG. This information sheet contains: Information about misophonia Checklist for misophonia Support for misophonia Web-resources for educators What is misophonia? Misophonia is a sound-sensitivity condition which causes an unusually strong aversion to particular sounds 1. For people with misophonia, sounds like chewing, for example, can cause extreme anger, disgust or even fear 1. Misophonia trigger-sounds are typically human-made, such as eating- noises, throat and nasal sounds, rustling, or tapping2. Misophonia ` typically emerges during childhood or adolescence, and can improve or worsen over time3. Although misophonia is not a disease, it has a known neurological basis4 and is recognised by health bodies such as the NHS (UK National Health Service) and the British Tinnitus Assocaition5. Below is a checklist for adults
    [Show full text]
  • A Consensus Definition of Misophonia: Using a Delphi Process to Reach Expert Agreement
    medRxiv preprint doi: https://doi.org/10.1101/2021.04.05.21254951; this version posted April 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . A Consensus Definition of Misophonia: Using a Delphi Process to Reach Expert Agreement Authors: Susan Swedo1, David M. Baguley2, Damiaan Denys3, Laura J. Dixon4, Mercede Erfanian5, Alessandra Fioretti6, Pawel J. Jastreboff7, Sukhbinder Kumar8, M. Zachary Rosenthal9, Romke Rouw10, Daniela Schiller11, Julia Simner12, Eric A. Storch13, Steven Talylor14, Kathy R. Vander Werff15, Sylvina M. Raver*16 Affiliations: 1PANDAS Physician Network, Mooresville, NC, United States Pediatrics and Developmental Neuroscience Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, United States 2Hearing Sciences, Mental Health and Clinical Neurosciences, School of Medicine, University of Nottingham, Nottingham, United Kingdom NIHR Biomedical Research Centre, School of Medicine, University of Nottingham, Nottingham, United Kingdom Nottingham Audiology Services, Nottingham University Hospitals, Nottingham, United Kingdom 3Department of Psychiatry, Amsterdam University Medical Center, Amsterdam, The Netherlands 4Department of Psychology, University of Mississippi, Oxford, MS, United States 5UCL Institute for Environmental Design and Engineering, University College London, London United
    [Show full text]
  • Misophonia Phenomenology, Impact, and Clinical Correlates
    Misophonia phenomenology and impact Misophonia phenomenology, impact, and clinical correlates James M. Claiborn1, Thomas H. Dozier2, 1Independent practice, South Portland, ME, USA 2Misophonia Institute, Livermore, CA, USA *Corresponding author: James M. Claiborn, 6 D St. South Portland ME 04106, USA phone: 1- 207-799-0408, fax: 1-207-767-7002, email: [email protected] Key Words: misophonia, anger, comorbidity, phenomenology, impairment Conflict of Interest: Thomas Dozier is a misophonia treatment provider and owner of several smartphone apps directed toward individuals with misophonia. 1 Misophonia phenomenology and impact Abstract This research study was conducted to determine the effect on quality of life and gather information about the characteristics of misophonia. It was a large scale, online survey with over 1,000 respondents. The key findings were as follows. 1) People suffering with misophonia experience a reduced quality of life. 2) Misophonia can develop at any age, with the median and mode age of onset at 9-10 years. 3) Treatments to date had been generally ineffective, but some reported treatment being very helpful. 4) Eating stimuli are by far the most common, with 96% of people reporting this trigger. 5) Most people reported physical reactions as a part of their response to triggers. 2 Misophonia phenomenology and impact If you are looking for a definition of misophonia, it is a severe sensitivity to specific soft sounds and visual images. It also includes other forms of stimuli that cause an immediate extreme reaction. When a person hears the sounds, the person has a very strong emotional reaction such as hate, anger, anxiety, rage, and resentment.
    [Show full text]
  • Are AMPA Receptor Positive Allosteric Modulators Potential Pharmacotherapeutics for Addiction?
    Pharmaceuticals 2014, 7, 29-45; doi:10.3390/ph7010029 OPEN ACCESS pharmaceuticals ISSN 1424-8247 www.mdpi.com/journal/pharmaceuticals Review Are AMPA Receptor Positive Allosteric Modulators Potential Pharmacotherapeutics for Addiction? Lucas R. Watterson 1,* and M. Foster Olive 1,2 1 Department of Psychology, Behavioral Neuroscience Area, Arizona State University, Tempe, AZ 85287, USA 2 Interdisciplinary Graduate Program in Neuroscience, Arizona State University, Tempe, AZ 85287, USA * Author to whom correspondence should be addressed; E-Mail:[email protected]; Tel.: +1-480-965-2573. Received: 28 October 2013; in revised form: 13 December 2013 / Accepted: 24 December 2013 / Published: 30 December 2013 Abstract: Positive allosteric modulators (PAMs) of α-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid (AMPA) receptors are a diverse class of compounds that increase fast excitatory transmission in the brain. AMPA PAMs have been shown to facilitate long-term potentiation, strengthen communication between various cortical and subcortical regions, and some of these compounds increase the production and release of brain-derived neurotrophic factor (BDNF) in an activity-dependent manner. Through these mechanisms, AMPA PAMs have shown promise as broad spectrum pharmacotherapeutics in preclinical and clinical studies for various neurodegenerative and psychiatric disorders. In recent years, a small collection of preclinical animal studies has also shown that AMPA PAMs may have potential as pharmacotherapeutic adjuncts to extinction-based or cue-exposure therapies for the treatment of drug addiction. The present paper will review this preclinical literature, discuss novel data collected in our laboratory, and recommend future research directions for the possible development of AMPA PAMs as anti-addiction medications.
    [Show full text]